SS-31 (elamipretide) , a mitochondria-targeted peptide that stabilizes cardiolipin to support energy production, became the first FDA-approved mitochondrial therapeutic in 2025, though only for the rare Barth syndrome, with the brain rationale still mechanistic and no cognitive trials
By contrast, Cora Health charges no membership or platform fee its monthly price is all-inclusive and already covers the provider consultation, medication, shipping, and ongoing monitoring
doesn't regulate off-label uses of H.G.H
When researchers tested it at higher doses, the results were jaw-dropping
By contrast, sellers of compounded GLP-1 products typically charge between $200 and $300 a month, and some less than that